Metformin and Colorectal Cancer
- PMID: 30405532
- PMCID: PMC6205961
- DOI: 10.3389/fendo.2018.00622
Metformin and Colorectal Cancer
Abstract
Colorectal Cancer (CRC) is one of the most frequently encountered neoplasms in humans. The incidence of CRC has been increasing and new strategies for prevention, including chemoprevention, are required to lower its incidence and associated mortality. Metformin is a biguanide compound commonly used for the treatment of diabetes mellitus. Many recent basic research, epidemiological and clinical trial studies have indicated that metformin has benefits not only in diabetes treatment, but also in lowering the risk of developing cancer (including CRC). These studies indicate that metformin may be a candidate chemoprevention agent for CRC. This review article shall discuss the present evidence of metformin treatment and CRC, as well as outline our challenge in the investigation of metformin use in chemoprevention therapy for colorectal tumors.
Keywords: basic research; chemoprevention; clinical trials; colorectal cancer; epidemiology; metfromin; review.
Figures
Similar articles
-
Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.Lancet Oncol. 2016 Apr;17(4):475-483. doi: 10.1016/S1470-2045(15)00565-3. Epub 2016 Mar 3. Lancet Oncol. 2016. PMID: 26947328 Clinical Trial.
-
Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population.Cancer. 2015 Apr 1;121(7):1071-8. doi: 10.1002/cncr.29165. Epub 2014 Nov 25. Cancer. 2015. PMID: 25424411 Free PMC article.
-
Role of gut microbiome in regulating the effectiveness of metformin in reducing colorectal cancer in type 2 diabetes.World J Clin Cases. 2020 Dec 26;8(24):6213-6228. doi: 10.12998/wjcc.v8.i24.6213. World J Clin Cases. 2020. PMID: 33392303 Free PMC article. Review.
-
Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?Curr Drug Targets. 2017;18(6):734-750. doi: 10.2174/1389450118666161205125548. Curr Drug Targets. 2017. PMID: 27919208 Review.
-
The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus.Int J Cancer. 2012 Aug 1;131(3):752-9. doi: 10.1002/ijc.26421. Epub 2011 Oct 20. Int J Cancer. 2012. PMID: 21913184
Cited by
-
Current trends and future prospects of drug repositioning in gastrointestinal oncology.Front Pharmacol. 2024 Jan 4;14:1329244. doi: 10.3389/fphar.2023.1329244. eCollection 2023. Front Pharmacol. 2024. PMID: 38239190 Free PMC article. Review.
-
Age-Specific Differences in the Risk of Colorectal Precursor Lesions Among Patients with Type 2 Diabetes Undergoing Surveillance Colonoscopy.Asian Pac J Cancer Prev. 2023 May 1;24(5):1769-1779. doi: 10.31557/APJCP.2023.24.5.1769. Asian Pac J Cancer Prev. 2023. PMID: 37247300 Free PMC article.
-
Association between visceral obesity, metformin use, and recurrence risk in early-stage colorectal cancer.Sci Rep. 2023 May 24;13(1):8401. doi: 10.1038/s41598-023-34690-y. Sci Rep. 2023. PMID: 37225730 Free PMC article.
-
Differential Interactome Based Drug Repositioning Unraveled Abacavir, Exemestane, Nortriptyline Hydrochloride, and Tolcapone as Potential Therapeutics for Colorectal Cancers.Front Bioinform. 2021 Sep 14;1:710591. doi: 10.3389/fbinf.2021.710591. eCollection 2021. Front Bioinform. 2021. PMID: 36303724 Free PMC article.
-
Asparagine, colorectal cancer, and the role of sex, genes, microbes, and diet: A narrative review.Front Mol Biosci. 2022 Aug 25;9:958666. doi: 10.3389/fmolb.2022.958666. eCollection 2022. Front Mol Biosci. 2022. PMID: 36090030 Free PMC article. Review.
References
-
- Research WCRFAIfC. Colorectal Cancer 2011 Report. (2011).
Publication types
LinkOut - more resources
Full Text Sources
